Targets › VMAT2
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Feb 2027.
Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. (UniProt, Q05940)
Open in Phaseline: the race on VMAT2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neurocrine Biosciences | NBI-1065890 Vesicular monoamine transporter 2 (VMAT2) inhibitor | VMAT2 | Phase 2 | Tardive Dyskinesia | Feb 2027 |
Tardive Dyskinesia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.